{"id":44203,"date":"2025-10-23T20:10:01","date_gmt":"2025-10-23T12:10:01","guid":{"rendered":"https:\/\/flcube.com\/?p=44203"},"modified":"2025-10-23T20:10:01","modified_gmt":"2025-10-23T12:10:01","slug":"abbvies-select%e2%80%91switch-study-confirms-upadacitinib-outperforms-adalimumab-in-ra","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44203","title":{"rendered":"AbbVie\u2019s SELECT\u2011SWITCH Study Confirms Upadacitinib Outperforms Adalimumab in RA"},"content":{"rendered":"\n

AbbVie (NYSE: ABBV<\/a>) announced positive topline data from its Phase\u202fIIIb\/IV head\u2011to\u2011head trial, SELECT\u2011SWITCH<\/strong>, comparing upadacitinib extended\u2011release (ER)<\/strong> 15\u202fmg once daily to adalimumab<\/strong> 40\u202fmg every other week in adults with moderately to severely active rheumatoid arthritis (RA) on stable methotrexate (MTX) who had an inadequate response or intolerance to a tumor necrosis factor inhibitor (TNFi) other than adalimumab.<\/p>\n\n\n\n

Key Findings<\/strong><\/h2>\n\n\n\n
Metric<\/th>Upadacitinib ER<\/th>Adalimumab<\/th>Statistical Significance<\/th><\/tr><\/thead>
Low Disease Activity (LDA) \/ Remission<\/strong><\/td>43.3\u202f% (\u2265\u202fDAS28\u2011CRP\u202f\u2264\u202f3.2)<\/td>22.4\u202f%<\/td>p\u202f<\u202f0.001<\/td><\/tr>
Remission (DAS28\u2011CRP\u202f<\u202f2.6)<\/strong><\/td>28.4\u202f%<\/td>14.5\u202f%<\/td>p\u202f<\u202f0.001<\/td><\/tr>
Primary Endpoint (Week\u202f12)<\/strong><\/td>Met<\/td>\u2013<\/td>\u2013<\/td><\/tr>
Safety<\/strong><\/td>No new risks<\/td>No new risks<\/td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The study demonstrated that at Week\u202f12, the proportion of patients achieving low disease activity and remission with upadacitinib ER was nearly double that with adalimumab, meeting the primary endpoint and securing positive results on most ranked secondary endpoints.<\/p>\n\n\n\n

Study Design<\/strong><\/h2>\n\n\n\n